Chronic inflammation and autoimmune diseases present significant challenges in drug discovery and therapeutic development. With validated in vivo disease models covering multiple disease areas, we enable pharmaceutical and biotech companies to make informed, data-driven decisions before clinical trials.
Inflammatory Bowel Disease (IBD) Models
Inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease are complex disorders requiring accurate preclinical models. We offer well-established IBD models to evaluate the efficacy of novel anti-inflammatory and immunomodulatory therapies:
- DSS-Induced Ulcerative Colitis (Mice): A chemically induced model replicating colonic inflammation seen in ulcerative colitis patients.
- TNBS-Induced Crohn’s Disease (Rat): Mimics the chronic, relapsing inflammation of Crohn’s disease.
- Oxazolone-Induced Colitis: A T-cell-mediated model used for studying immune mechanisms in colitis.
Skin Inflammation Models
Our skin inflammation models offer robust platforms for evaluating treatments for psoriasis, atopic dermatitis, and pruritus:
- Imiquimod-Induced Psoriasis (Mice): A widely used model for psoriasis research that closely resembles human disease pathology.
- IL-23 Induced Psoriasis (Mice): This mouse model is valuable for identifying and testing potential therapies for psoriasis, including IL-23 inhibitors.
- TPA-Induced Atopic Dermatitis (Mice): Used to study skin barrier dysfunction and inflammatory responses.
- Oxazolone-Induced Contact Dermatitis (Mice – Acute & Chronic): Models allergic contact dermatitis in different disease stages.
- Chloroquine-Induced Itch (Mice): Helps assess potential anti-pruritic drugs targeting neurogenic itch.
- Pruritus (Itch) – Histamine-Induced Model: Evaluates mechanisms of itch and potential therapeutic interventions.
Systemic Lupus Erythematosus (SLE) Models
SLE is a complex autoimmune disorder affecting multiple organs. Our preclinical models allow researchers to evaluate new therapies targeting immune dysfunction:
- MRL/lpr Mouse Model of SLE: A spontaneous lupus model with severe autoimmune pathology.
- NZBWF1/J Mouse Model of SLE: Mimics human lupus nephritis and systemic autoimmunity.
Respiratory Inflammation Models
Chronic lung inflammation and fibrosis contribute to severe respiratory diseases. Our models provide a foundation for studying anti-inflammatory and antifibrotic treatments:
- LPS-Induced Acute Lung Inflammation (Rat & Mouse): Models acute respiratory inflammation seen in ARDS and COPD.
- IPF: Bleomycin-Induced Lung Fibrosis: Mimics idiopathic pulmonary fibrosis for antifibrotic drug screening.
Joint Inflammation Models
Rheumatoid arthritis and other inflammatory joint diseases require robust preclinical models for therapy evaluation. Our arthritis models include:
- Collagen Type-II Induced Arthritis (CIA) in Mice: A widely used autoimmune arthritis model mimicking human RA.
- Adjuvant-Induced Arthritis (AIA) in Rats: A model for inflammatory arthritis used for anti-rheumatic drug screening.
- Collagen Antibody Induced Arthritis (CAIA) in Mice: A rapid-onset arthritis model for assessing therapeutic efficacy.
Multiple Sclerosis (MS) Models
Autoimmune demyelination is central to MS pathogenesis. Our MS models allow detailed investigation of neuroinflammation and myelin repair strategies:
- MOG35-55-Induced EAE (C57BL/6 Mice): A T-cell-mediated model for progressive MS studies.
- PLP139-151 Induced EAE (SJL/J Mice): A relapsing-remitting MS model useful for studying disease progression and treatment responses.
Why Choose Our InVivo Disease Models?
Clinically Relevant Models – Our models closely replicate human disease pathology, ensuring better translational success.
Comprehensive Coverage – From IBD and respiratory inflammation to MS and autoimmune disorders, we offer validated models across multiple indications.
Customizable Study Designs – Tailored protocols to meet specific research objectives and regulatory requirements.
Expert Scientific Support – Our experts guide you from model selection to data interpretation.
Frequently Asked Questions (FAQs)
1. How do I choose the most suitable in vivo disease model for my study?
Our team of experts will guide you in selecting the most appropriate model based on your research objectives, therapeutic targets, and disease pathology. We also offer customizable study designs to align with your specific requirements.
2. How well do these models replicate human disease conditions?
Our models are clinically relevant and designed to closely mimic human disease pathology, ensuring better translational success in drug development. Each model has been validated to provide meaningful preclinical data.
3. Can the study protocols be tailored to my specific needs?
Yes, we offer flexible and customizable study designs to accommodate specific research goals, drug mechanisms, and regulatory requirements. Our team works closely with you to optimize protocols.
4. What kind of data and analysis will I receive at the end of the study?
You will receive a comprehensive study report that includes raw data, statistical analysis, histopathological findings, biomarker evaluation, and expert interpretation to support your drug development decisions.
5. Do you provide regulatory support and guidance for preclinical studies?
Yes, we provide expert scientific support, including guidance on regulatory compliance, study design optimization, and data interpretation to help you progress towards clinical trials efficiently. Accelerate your drug development journey with proven in vivo models.
Accelerate Your Inflammation and Autoimmune Disease Models Today.